-
Phase 2
-
-
40-85Altersgruppe
-
47Standorte
-
Recruiting
Recruiting
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Key Inclusion Criteria: - Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability Key Exclusion Criteria: - Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant Note: Other protocol-defined inclusion/exclusion criteria apply
Experimental: BMS-986435
Placebo Comparator: Placebo